|
Re: Tivatinib (ARQ-197)
I found another article I xeroxed from the Pharmacy I last worked at about ARQ-197 (Tivatinib).
For one thing there were some prolonged stablization of disease when ARQ-197 was given in Pancreatic cancer which often has a quick clinical course. Ill have to search the for specific articles.
As far as breast cancer goes in pts treated with Herceptin and given ARQ-197 experimentally, the incidince of brain mets in one study was more than halved. It seems ARQ-197 has antimetastatic activity.
The list of side effects was more extensive.
Fatigue was most common (about 21%), Nausea (10%)
Diarrhea (6.4%), chills (4.3%), night sweats (4.3%)
Taste disturbances (4.3%), Decreased appetite (4.3%)
Neutopenia (2.1%), Anemia (2.1%) and increased liver enzymes (2.1%)
Paul
|
Hybrid Mode
